(RDCRN-6503) Targeted Therapy of Bronchiolitis Obliterans Syndrome (BOS)
Description: 

To determine if the combination treatment of inhaled flu ticas one,azithromycin, and montelukast (FAM) administered in post Hematopoietic Cell Transplantation (HCT) recipients after the diagnosis of new onset bronchiolitis obliterans syndrome (BOS) can decrease the rate of treatment failure relative to an estimated historical rate of 40% using current therapies.

Study Number: 

I 234413

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01307462

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.